Drug Pricing: Could Expedited Review Of Competing Brands Create The Desired Pressure?

Payer groups suggest during FDA's Hatch-Waxman meeting that agency prioritize NDAs moving into the same class to push prices lower.

US dollars and pills

Priority review of innovator products, a valuable tool for brand drug development, also may be able to help FDA fight the drug pricing problem.

Usually it is the brand industry that is considered at least partially responsible for the problem of rising drug prices,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access